ClinicalTrials.gg
RecruitingNCT07284082Updated Apr 22, 2026

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

An observational study in HIV, Menopause and Cardiovascular (CV) Risk, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University of California, San Francisco · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 77 studies in Carotid Artery Diseases with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Carotid Artery Diseases · United States.

Planned enrollment
26th of 34
90 · median 211
Started
2026
with 4 others
Observational
34 of 77
8 open now
Primary completion
2030-03
later than 17 of 17 live
Registered
73rd of 77
by date

Among the 77 studies in Carotid Artery Diseases with a site in United States, this one is the 26th largest by planned enrollment of the 34 observational ones that give a count, is one of 5 that started in 2026, is one of 34 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 73rd registered.

Carotid Artery Diseases

260 studies on the registry are indexed under Carotid Artery Diseases; 60 are open to participants now.

Browse Carotid Artery Diseases studies →

Open to participants now

15 of the 77 studies in Carotid Artery Diseases with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Carotid Artery Diseases studies recruiting now, 33 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Carotid Artery Diseases with a site in United States, or all of them as a file.
02

Study summary

Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.

03

Conditions studied

  • HIV
  • Menopause
  • Cardiovascular (CV) Risk
  • Carotid Arteriosclerosis
  • Body Composition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with HIV who are enrolled in the MWCCS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 90 non-pregnant women with (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.

Exclusion criteria

Exclusion Criteria:

  • Women who are not virally suppressed ( RNA >200 copies/mL)
  • Women who are not on antiretroviral therapy
  • Women who have a history of hysterectomy or oophorectomy
  • Women who are receiving treatment for active cancer or tuberculosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • MACS-WIHS Combined Cohort Study

    Diagnostic Test: Whole body MRI

Interventions

  • Diagnostic testWhole body MRI

    Whole body MRI will be performed as part of a study protocol

06

What researchers measure

Primary outcomes

  1. Markers of immune activation and inflammation

    sCD14 (monocyte activation), sCD163 (M2 macrophage activation), CRP (inflammation), IL-6 (inflammation), IP-10 (interferon-inducible protein), TNFα (inflammation), MCP-1 (inflammation), sTNFRI \& RII (inflammation). There are no units as they will be normalized based upon their interquartile range.

    Time frame: These markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2030, 46 months after the start.

Of 45 observational studies under Carotid Artery Diseases, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 94. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 16, 2025
StartActual
Apr 17, 2026
Primary completionEst.
Mar 1, 2030
CompletionEst.
Mar 1, 2030
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07284082
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Apr 17, 2026
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Apr 22, 2026

Study contacts

Rebecca A Abelman, MD
Contact
rebecca.abelman@ucsf.edu
415-221-4810 ext. 23613
Stacy Polos
Contact
stacy.polos@ucsf.edu
415-689-0915
Rebecca Abelman, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion